Related references
Note: Only part of the references are listed.Serum bicarbonate and cardiovascular events in hypertensive adults: results from the Systolic Blood Pressure Intervention Trial
Mirela Dobre et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney Disease
Gerrit Klaerner et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial
Donald E. Wesson et al.
LANCET (2019)
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Andrew A. House et al.
KIDNEY INTERNATIONAL (2019)
Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension
Donald E. Wesson et al.
LANCET (2019)
Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD
David A. Bushinsky et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Mild metabolic acidosis impairs the beta-adrenergic response in isolated human failing myocardium
Hanna Schotola et al.
CRITICAL CARE (2012)
High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database
J. Thomas Heywood et al.
JOURNAL OF CARDIAC FAILURE (2007)
Control of hypertension in adults with chronic kidney disease in the United States
CA Peralta et al.
HYPERTENSION (2005)
Share Paper
